Advertisement

Born from research in Australia, new Cambridge startup ImmusanT Inc. has launched to commercialize a therapy that aims to treat celiac disease like a simple allergy with regular injections of a therapy.

According to Leslie J. Williams, founder, president and CEO of ImmusanT, what attracted her to the core concepts behind the company was “the science – the simplicity and the elegance of the science.” That science came from Nexpep Pty. Ltd., based in Melbourne, Australia, which had been founded by Bob Anderson, a gastroenterologist and an expert in immunology and clinical management of celiac disease at The Walter and Eliza Hall Institute of Medical Research.

SOURCE

Advertisement
Advertisement